Results 111 to 120 of about 861 (122)
Some of the next articles are maybe not open access.
INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Retina, 2019Purpose: To evaluate the 52-week safety and efficacy of intravitreal ziv-aflibercept in patients with neovascular age-related macular degeneration. Methods: All patients received three monthly intravitreal injections of 0.05 mL of ziv-aflibercept (1.25 mg) followed by a pro re nata ...
João R, de Oliveira Dias +9 more
openaire +2 more sources
INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA
Retina, 2016Diabetic macular edema is the leading cause of blindness in young adults in developed countries. Beyond metabolic control, several therapies have been studied such as laser treatment and intravitreal injections of corticosteroids or anti-vascular endothelial growth factor drugs.
Gabriel Costa de, Andrade +5 more
openaire +2 more sources
Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy
British Journal of Ophthalmology, 2018AimTo assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.MethodsIn this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the
Ahmad M, Mansour +4 more
openaire +2 more sources
Ziv-aflibercept: binding to more than VEGF-A—does more matter?
Nature Reviews Clinical Oncology, 2012The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in non-small-cell lung cancer.
Jeffrey M, Clarke, Herbert I, Hurwitz
openaire +2 more sources
Long-term safety and efficacy of ziv-aflibercept in retinal diseases
British Journal of Ophthalmology, 2017To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept.Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three ...
Ahmad M Mansour +5 more
openaire +2 more sources
Regression of Inflamed Pterygia by Frequent High-Dose Intralesional Ziv-Aflibercept
Cornea, 2017Purpose: Intralesional single low-dose vascular endothelial growth factor antagonists have traditionally failed in causing regression of pterygia. The current pilot study investigates the role of high-dose repeated intralesional ziv-aflibercept in causing regression of inflamed or recurring pterygia.
openaire +2 more sources
Use of Ziv Aflibercept in Different Retinal Diseases
Case Medical Research, 2020openaire +1 more source
Ziv-aflibercept is effective in platinum-resistant SCLC
Nature Reviews Clinical Oncology, 2014openaire +1 more source